QNRX Stock Overview
A clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Quoin Pharmaceuticals, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.58 |
| 52 Week High | US$6.18 |
| 52 Week Low | US$0.48 |
| Beta | 1.89 |
| 11 Month Change | -23.02% |
| 3 Month Change | -3.26% |
| 1 Year Change | -87.21% |
| 33 Year Change | -99.91% |
| 5 Year Change | n/a |
| Change since IPO | -99.97% |
Recent News & Updates
Shareholder Returns
| QNRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.7% | 2.4% | 2.2% |
| 1Y | -87.2% | 16.2% | 31.7% |
Return vs Industry: QNRX underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: QNRX underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| QNRX volatility | |
|---|---|
| QNRX Average Weekly Movement | 23.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: QNRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: QNRX's weekly volatility has increased from 16% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 4 | Michael Myers | quoinpharma.com |
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.
Quoin Pharmaceuticals, Ltd. Fundamentals Summary
| QNRX fundamental statistics | |
|---|---|
| Market cap | US$3.13m |
| Earnings (TTM) | -US$8.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs QNRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QNRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.70m |
| Earnings | -US$8.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.72 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 56.5% |
How did QNRX perform over the long term?
See historical performance and comparison